Author

D. Barras

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Immunology· 2 Cancer Biology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:cell type annotation· 3 Research Focus:cell-cell communication· 3 Research Focus:differential expression· 3 Organism:human· 3 Assay:scRNA-seq· 3 Research Focus:clustering· 2 Approach:experimental assay· 2 Approach:statistical model· 2

Frequent Co-Authors

D. Dangaj Laniti· 3 shared E. Ghisoni· 3 shared F. Benedetti· 3 shared G. Coukos· 3 shared M. Bassani-Sternberg· 3 shared N. Fahr· 3 shared A. Harari· 2 shared A. Orcurto· 2 shared

Activity by Year

2022-2024 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

3 shared papersImmunology

D. Dangaj Laniti

Mutual co-authors in cluster

Author profile →

3 papers

Recent·Most cited

Myeloid cell networks determine reinstatement of original immune environments in recurrent ovarian cancer

E. Ghisoni, F. Benedetti, A. Minasyan, P. Cunnea, A. J. Grimm, N. Fahr, M. Desbuisson, C. Capt, N. Rayroux, D. C. Gulhan, J. Dagher, D. Barras, M. Morotti, J. A. Marin Jimenez, F. De Carlo, , D. Dangaj Laniti

The paper identifies immune phenotypes and myeloid cell networks in recurrent ovarian cancer that influence prognosis and immune environment reinstatement.

bioRxiv · May 2, 2024 · PreprintImmunology

Tumor-reactive clonotype dynamics underlying clinical response to TIL therapy in melanoma

J. Chiffelle, D. Barras, R. Petremand, A. Orcurto, S. Bobisse, M. Arnaud, A. Auger, B. Navarro Rodrigo, E. Ghisoni, C. Sauvage, D. Saugy, A. Michel, B. Murgues, N. Fahr, M. Imbimbo, , G. Coukos

This study tracks tumor-reactive TIL clonotypes in melanoma patients before and after TIL-ACT to identify factors associated with clinical response.

bioRxiv · Jul 21, 2023 · PreprintCancer Biology

Tumor Microenvironment Cellular Crosstalk Predicts Response to Adoptive TIL Therapy in Melanoma

D. Barras, E. Ghisoni, J. Chiffelle, A. Orcurto, J. Dagher, N. Fahr, F. Benedetti, I. Crespo, S. Zimmermann, R. Duran, M. Imbimbo, M. Ochoa De Olza, B. Navarro, K. Homiscko, S. Bobisse, , G. Coukos

This study identifies CD8+ TIL-myeloid cell networks as predictors of response to adoptive TIL therapy in melanoma using single-cell RNA-seq and spatial proteomic analyses.

bioRxiv · Dec 23, 2022 · PreprintImmunology